Loading...
•
Jun 30, 2020
Leap Therapeutics Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020.
Key Takeaways
Leap Therapeutics reported a net loss of $6.5 million for the second quarter of 2020, compared to $8.4 million for the same period in 2019. The company's cash, cash equivalents, and marketable securities totaled $64.9 million at June 30, 2020.
Partnership with BeiGene for DKN-01 is progressing well.
First patient expected to be dosed this quarter in the combination study of DKN-01 plus tislelizumab for gastric or gastroesophageal junction cancer.
DKN-01 shows potential to treat multiple biomarker-defined cancers.
Company is well funded to drive development forward following recent public offering.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...